| Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources G Souillet, N Guffon, I Maire, M Pujol, P Taylor, F Sevin, N Bleyzac, ... Bone marrow transplantation 31 (12), 1105-1117, 2003 | 246 | 2003 |
| Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens N Bleyzac, G Souillet, P Magron, A Janoly, P Martin, Y Bertrand, ... Bone marrow transplantation 28 (8), 743-751, 2001 | 151 | 2001 |
| Azithromycin for COVID-19: more than just an antimicrobial? N Bleyzac, S Goutelle, L Bourguignon, M Tod Clinical drug investigation 40, 683-686, 2020 | 137 | 2020 |
| Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric … A Paci, G Vassal, D Moshous, JH Dalle, N Bleyzac, B Neven, ... Therapeutic drug monitoring 34 (2), 198-208, 2012 | 92 | 2012 |
| HSV excretion after bone marrow transplantation: a 4-year survey F Morfin, K Bilger, A Boucher, A Thiebaut, F Najioullah, N Bleyzac, ... Journal of clinical virology 30 (4), 341-345, 2004 | 66 | 2004 |
| Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model S Corvaisier, PH Maire, MY Bouvier d’Yvoire, X Barbaut, N Bleyzac, ... Antimicrobial agents and chemotherapy 42 (7), 1731-1737, 1998 | 66 | 1998 |
| Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software M Neely, M Philippe, T Rushing, X Fu, M van Guilder, D Bayard, ... Therapeutic drug monitoring 38 (3), 332-342, 2016 | 64 | 2016 |
| Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated … P Martin, N Bleyzac, G Souillet, C Galambrun, Y Bertrand, PH Maire, ... Bone Marrow Transplantation 32 (8), 777-784, 2003 | 60 | 2003 |
| Cyclosporin A inhibits dendritic cell maturation promoted by TNF-α or LPS but not by double-stranded RNA or CD40L K Duperrier, A Farre, J Bienvenu, N Bleyzac, J Bernaud, L Gebuhrer, ... Journal of leukocyte biology 72 (5), 953-961, 2002 | 58 | 2002 |
| Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors P Martin, N Bleyzac, G Souillet, C Galambrun, Y Bertrand, PH Maire, ... Bone marrow transplantation 32 (9), 881-887, 2003 | 57 | 2003 |
| New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detection P Favetta, J Guitton, N Bleyzac, C Dufresne, J Bureau Journal of Chromatography B: Biomedical Sciences and Applications 751 (2 …, 2001 | 54 | 2001 |
| Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study V Bertholle-Bonnet, N Bleyzac, C Galambrun, V Mialou, Y Bertrand, ... Therapeutic drug monitoring 29 (2), 177-184, 2007 | 49 | 2007 |
| Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma N Bleyzac, P Barou, G Aulagner Journal of Chromatography B: Biomedical Sciences and Applications 742 (2 …, 2000 | 47 | 2000 |
| In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates S Goutelle, L Bourguignon, N Bleyzac, J Berry, F Clavel-Grabit, M Tod, ... The AAPS journal 15, 415-426, 2013 | 46 | 2013 |
| Diurnal changes in the pharmacokinetic behavior of amikacin N Bleyzac, B Allard-Latour, A Laffont, J Mouret, R Jelliffe, P Maire Therapeutic Drug Monitoring 22 (3), 307-312, 2000 | 44 | 2000 |
| High-performance liquid chromatographic determination of ganciclovir in plasma R Boulieu, N Bleyzac, S Ferry Journal of chromatography B: Biomedical sciences and applications 567 (2 …, 1991 | 41 | 1991 |
| Proton pump inhibitors are risk factors for viral infections: even for COVID-19? B Charpiat, N Bleyzac, M Tod Clinical drug investigation 40, 897-899, 2020 | 40 | 2020 |
| Medication adherence in pediatric transplantation and assessment methods: a systematic review D Hoegy, N Bleyzac, P Robinson, Y Bertrand, C Dussart, ... Patient preference and adherence, 705-719, 2019 | 37 | 2019 |
| Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children M Philippe, S Goutelle, J Guitton, X Fonrose, C Bergeron, P Girard, ... Bone Marrow Transplantation 51 (1), 72-78, 2016 | 35 | 2016 |
| Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children E Bernard, S Goutelle, Y Bertrand, N Bleyzac Annals of Pharmacotherapy 48 (12), 1580-1584, 2014 | 34 | 2014 |
